Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.

Bruno VincenziMargherita NanniniGiuseppe BadalamentiGiovanni GrignaniElena FumagalliSilvia GasperoniLorenzo D'AmbrosioLorena IncorvaiaMarco StellatoMariella Spalato CerusoAndrea NapolitanoSergio ValeriDaniele SantiniGiuseppe ToniniPaolo Giovanni CasaliAngelo Paolo Dei TosMaria Abbondanza Pantaleo

Published in: Therapeutic advances in medical oncology (2018)

Our retrospective data confirm that imatinib rechallenge is a reasonable option in advanced GIST. The prognostic value of the specific KIT mutations was confirmed in our series.

Keyphrases

chronic myeloid leukemia
electronic health record
cross sectional
renal cell carcinoma
metastatic renal cell carcinoma
metastatic colorectal cancer
data analysis